Bryan, Garnier & Co acted as Sole Financial Advisor to Amplexor Life Sciences and its shareholder Acolad on the sale of the company to ArisGlobal, a Group backed by Nordic Capital

ArisGlobal, a portfolio company of Nordic Capital and leading provider of life sciences software designed to automate core drug development functions with its end-to-end technology platform LifeSphere® has made the acquisition from Acolad of Amplexor Life Sciences (LS), a global provider of regulatory, quality, and safety software solutions, serving and trusted by pharmaceutical, biotechnology, and medical device companies.

The integration of the regulatory product lines will bring a distinct set of benefits to customers. LifeSphere users are now gaining access to enhanced publishing and labeling capabilities; in addition to a robust Quality Management System (QMS) from Amplexor LS. Amplexor LS’s regulatory customers can now connect to even wider functionality through ArisGlobal’s market leading LifeSphere platform including access to state-of-the-art Intelligent Content management, Safety, Medical Affairs and Clinical solutions.

This combined product ecosystem provides a new opportunity for life sciences companies, bringing together best in breed solutions to form a cohesive solution serving customers’ regulatory needs. It also represents many years of industry expertise, software innovation, and customer excellence from ArisGlobal and Amplexor Life Sciences. This move will accelerate both companies’ roadmaps and increase efficiency in bringing new therapies to the market.

Bryan, Garnier & Co acted as Sole Financial Advisor to Amplexor Life Sciences and its shareholder Acolad on the sale of the company to ArisGlobal, a Group backed by Nordic Capital.

Bryan, Garnier & Co organized, prepared and led a competitive process involving several national and international trade buyers able to support the company’s growth and development strategy.

This marks another landmark transaction for Bryan, Garnier & Co’s software practice and is a further demonstration of its expertise in strategic-led buy-out transactions. Other notable software transactions include the acquisition of Brainwave GRC by Radiant Logic (a portfolio company of TA Associates), the acquisition of Groupe Lacour by Carlyle Europe Technology Partners, the investment of EMZ in Groupe Positive (ex-Groupe Sarbacane), the disposal of Mailinblack to Apax Partners, the acquisition of in CAST Software by Bridgepoint Development Capital, the sale of Horizon Software to Sagard NewGen, the investment of Cathay Capital, Sagard NewGen and Eurazeo in Dilitrust, the investment of MBO&Co in Praxedo, the investment of Five Arrows Growth Capital in Padoa and the sale of Eudonet to Montagu.

"We are grateful to Bryan Garnier's team commitment in helping us find the best partner for our growth journey while ensuring a strong alignment of all parties throughout the process. As our new majority shareholder, Columna will accelerate Physidia’s international expansion and bring us closer to fulfilling our ultimate mission of providing dialysis patients worldwide with flexibility, freedom, and better quality of life."

— Didier Candelot - CEO of Physidia

Amplexor Life Sciences is a global provider of regulatory, quality and safety software solutions, serving and trusted by pharmaceutical, biotechnology and medical device companies for over 30 years. Its holistic Life Sciences Suite of solutions helps life sciences organizations to be efficient with launching products and breaking into new markets quickly while ensuring quality, efficacy, and safety through end-to-end support to product lifecycle processes, data and content management. Amplexor Life Sciences was part of Acolad.

ArisGlobal, a portfolio company of Nordic Capital, is the market leader in Drug Safety solutions worldwide and is transforming the way today’s most successful Life Sciences companies develop breakthroughs and bring new products to market. Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan, and China

Nordic Capital is a leading private equity investor with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a long history. Focus sectors are Healthcare, Technology & Payments, Financial Services, and selectively, Industrial & Business Services. Key regions are Europe and globally for Healthcare and Technology & Payments investments. Since inception in 1989, Nordic Capital has invested EUR 22 billion in over 130 investments. Nordic Capital Advisors have local offices in Sweden, the UK, the US, Germany, Denmark, Finland, Norway and South Korea.